Literature DB >> 21533654

[Treatment of advanced metastatic melanoma].

S Ugurel1, J C Becker.   

Abstract

In the past therapy of advanced melanoma with distant metastases was characterized by limited success. In recent years the increased understanding of the pathogenesis of melanoma as well as tumor immunology, however, has allowed the development of new promising therapeutic options for certain subgroups of melanoma patients. In the present review these molecular-targeted and immune-modulating therapies, as well as already established therapies such as radiation or chemotherapy, will be discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533654     DOI: 10.1007/s00105-010-2041-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  28 in total

1.  Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

Authors:  D Schadendorf; S Ugurel; B Schuler-Thurner; F O Nestle; A Enk; E-B Bröcker; S Grabbe; W Rittgen; L Edler; A Sucker; C Zimpfer-Rechner; T Berger; J Kamarashev; G Burg; H Jonuleit; A Tüttenberg; J C Becker; P Keikavoussi; E Kämpgen; G Schuler
Journal:  Ann Oncol       Date:  2006-01-17       Impact factor: 32.976

2.  Major response to imatinib mesylate in KIT-mutated melanoma.

Authors:  F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

3.  Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.

Authors:  Patrick Terheyden; Roland Houben; Parisa Pajouh; Christoph Thorns; Detlef Zillikens; Jürgen C Becker
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

4.  Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study.

Authors:  Jeffrey C Buchsbaum; John H Suh; Shih-Yuan Lee; Mark A Chidel; John F Greskovich; Gene H Barnett
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

5.  Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Authors:  Ulrich Keilholz; Cornelis J A Punt; Martin Gore; Wim Kruit; Poulam Patel; Danielle Lienard; Jose Thomas; Thomas M Proebstle; Alexander Schmittel; Dirk Schadendorf; Thierry Velu; Sylvie Negrier; Ulrich Kleeberg; Frederic Lehman; Stefan Suciu; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

6.  Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.

Authors:  Agop Y Bedikian; Marcella M Johnson; Carla L Warneke; Susan McIntyre; Nicholas Papadopoulos; Wen-Jen Hwu; Kevin Kim; Patrick Hwu
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

Review 7.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

Authors:  Thomas K Eigentler; Ulrich M Caroli; Peter Radny; Claus Garbe
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

Review 8.  5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.

Authors:  S K Carter; M A Friedman
Journal:  Eur J Cancer       Date:  1972-02       Impact factor: 9.162

9.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

10.  Lack of clinical efficacy of imatinib in metastatic melanoma.

Authors:  S Ugurel; R Hildenbrand; A Zimpfer; P La Rosée; P Paschka; A Sucker; P Keikavoussi; J C Becker; W Rittgen; A Hochhaus; D Schadendorf
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

View more
  1 in total

1.  [Personalized therapy concepts for malignant melanoma].

Authors:  M Schlaak; N Kreuzberg; C Mauch; P Kurschat
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.